Chinese patients receiving androgen deprivation therapy (ADT) for prostate cancer are exposed to increased risk of new-onset diabetes mellitus (DM), hyperlipidaemia and hypertension (HTN), as well as a higher likelihood of step-up pharmacotherapy for these pre-existing conditions, according to a prospective multicentre cohort study by the Chinese University of Hong Kong (CUHK) and Tuen Mun Hospital.